2024
Why do older adults stop cancer screening? Findings from the Medicare Current Beneficiary Survey
Belliveau O, Richman I. Why do older adults stop cancer screening? Findings from the Medicare Current Beneficiary Survey. Journal Of The American Geriatrics Society 2024 PMID: 39444166, DOI: 10.1111/jgs.19239.Peer-Reviewed Original ResearchMedicare Current Beneficiary SurveyCancer screeningHealth statusScreening cessationPhysician recommendationBeneficiary SurveyEducational attainmentHistory of breast cancerBreast cancer screeningHigher educational attainmentNationally representative dataHistory of prostate cancerDiscontinue screeningScreening mammographyOlder adultsImprove communicationPatient preferencesWeighted populationPrimary outcomeRepresentative dataPhysiciansHealthProstate cancerBreast cancerMedicareACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update
Imaging P, Niell B, Jochelson M, Amir T, Brown A, Adamson M, Baron P, Bennett D, Chetlen A, Dayaratna S, Freer P, Ivansco L, Klein K, Malak S, Mehta T, Moy L, Neal C, Newell M, Richman I, Schonberg M, Small W, Ulaner G, Slanetz P. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update. Journal Of The American College Of Radiology 2024, 21: s126-s143. PMID: 38823941, DOI: 10.1016/j.jacr.2024.02.019.Peer-Reviewed Original ResearchConceptsReduce breast cancer mortalityRecommendation of mammographyBreast cancerBreast cancer mortalityBreast cancer riskBreast cancer screeningDigital breast tomosynthesisEvidence-based guidelinesAmerican College of Radiology Appropriateness CriteriaPeer-reviewed journalsMultidisciplinary expert panelRAND/UCLA Appropriateness Method User ManualMultiple different imaging modalitiesPeer-reviewed literatureScreening recommendationsCancer screeningCancer mortalityCancer riskGuideline developmentAppropriateness of imagingRecommendations AssessmentBreast tomosynthesisEstablished methodology principlesExpert panelAmerican College
2023
Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancer
2022
Insurance Coverage Mandates and the Adoption of Digital Breast Tomosynthesis
Richman IB, Long JB, Kyanko KA, Xu X, Gross CP, Busch SH. Insurance Coverage Mandates and the Adoption of Digital Breast Tomosynthesis. JAMA Network Open 2022, 5: e224208. PMID: 35333358, PMCID: PMC8956980, DOI: 10.1001/jamanetworkopen.2022.4208.Peer-Reviewed Original ResearchConceptsCoverage mandateCohort studyBreast cancerPocket paymentsDigital breast tomosynthesisInsurance coveragePoints 2 yearsAffordable Care ActMAIN OUTCOMEScreening mammogramsStudy periodDirect costsBreast tomosynthesisPatient ProtectionCare ActWomenCancerAssociationYearsPrivate insurersPatientsCost sharing
2021
Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women
Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X, Busch SH, Gross CP, Richman IB. Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women. Journal Of General Internal Medicine 2021, 37: 1870-1876. PMID: 34595682, PMCID: PMC8483166, DOI: 10.1007/s11606-021-07132-6.Peer-Reviewed Original ResearchConceptsWomen 75Older womenBreast cancerAdditional cancersSubsequent imagingWomen 67Stage ITime of diagnosisEarly-stage cancerHigh rateCancer detectionConclusionsBreast cancerPrior cancerPotential confoundersScreening outcomesHealth outcomesService beneficiariesComparative effectivenessScreening mammogramsAge groupsCancerLogistic regressionResultsOur studyWomenBreast tomosynthesis
2020
Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Internal Medicine 2020, 180: 799-801. PMID: 32202606, PMCID: PMC7147248, DOI: 10.1001/jamainternmed.2020.0262.Peer-Reviewed Original Research
2019
Association of State Dense Breast Notification Laws With Supplemental Testing and Cancer Detection After Screening Mammography.
Busch SH, Hoag JR, Aminawung JA, Xu X, Richman IB, Soulos PR, Kyanko KA, Gross CP. Association of State Dense Breast Notification Laws With Supplemental Testing and Cancer Detection After Screening Mammography. American Journal Of Public Health 2019, 109: 762-767. PMID: 30896987, PMCID: PMC6459654, DOI: 10.2105/ajph.2019.304967.Peer-Reviewed Original ResearchConceptsSupplemental screeningCancer detectionMore breast cancersMagnetic resonance imagingPossible benefitsBreast cancerSupplemental ultrasoundBreast biopsySupplemental testingResonance imagingUse of ultrasoundLogistic regressionScreening mammographyCancer diagnosisUltrasoundSignificant differencesSupplemental testsMore ultrasoundMammographyUS statesBreast cancer detectionMammogramsAssociationScreeningBiopsy
2018
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancer
2016
Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry
Richman I, Asch SM, Bendavid E, Bhattacharya J, Owens DK. Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry. Journal Of General Internal Medicine 2016, 32: 603-609. PMID: 27844260, PMCID: PMC5442000, DOI: 10.1007/s11606-016-3904-y.Peer-Reviewed Original ResearchConceptsBreast density notification legislationProportion of womenBreast cancer stageCancer stageBreast cancerMetastatic diseaseEnd Results (SEER) Program registryTime of diagnosisInvasive breast cancerBreast density notification lawsSEER registryControl stateDuctal carcinomaInvasive cancerProgram registryAge 40Potential confoundingLimited followSignificant associationIntervention statesDense breastsResultsOur studyCancerDiagnosisEarly detection